Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab
Abstract Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR...
Gespeichert in:
| Veröffentlicht in: | Breast (Edinburgh) 2015-02, Vol.24 (1), p.18-23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 18 |
| container_title | Breast (Edinburgh) |
| container_volume | 24 |
| creator | Shinde, Arvind M Zhai, Jing Yu, Kim Wai Frankel, Paul Yim, John H Luu, Thehang Kruper, Laura Vito, Courtney Shaw, Sally Vora, Nayana L Kirschenbaum, Michele Somlo, George |
| description | Abstract Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC. |
| doi_str_mv | 10.1016/j.breast.2014.10.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4596816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S096097761400188X</els_id><sourcerecordid>1645228702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-513094e6d816a01f08bfd3ac39bc31024d1c3376a64ab184630d0bf4c04d65243</originalsourceid><addsrcrecordid>eNqFUsuO1DAQjBCIXRb-ACEfOWyGdux4MhcktFpYpJVAPCRuluN0Jh4SO9jOwPC1fArOZhkeF05-lKur3F1Z9pjCigIVz3ar2qMKcVUA5elqBVDdyU5pyYqcQQV3s1PYCMg367U4yR6EsAOADRPV_eykKLlYM8pOsx9vVexc77ZGE-2GsceIxGMYnQ1poyIGYiyJ3iQot7hV0ezxnFxdvivy0QWzHJVtSOf84OzM1jhG548wWYwSraxGH4hqI_pEiZ1X-qB7YzFvPSKx6FSzm_YJIrrDwcUOvRoP5KuJXaL72o19MmBv9EaVqFF9w37Bnb9Z3RST3aQ3fZ8GVT_M7rWqD_jodj3LPr68_HBxlV-_efX64sV1rktaxbykDDYcRVNRoYC2UNVtw5Rmm1ozCgVvqGZsLZTgqqYVFwwaqFuugTeiLDg7y54vdcepHrDRaJOJXo7eDMofpFNG_o1Y08mt20tebkQSTQWe3hbw7suEIcrBBI19r1JbpiCp4GVRVGso0lO-PNXeheCxPcpQkHM45E4uPZdzOObbFI5Ee_KnxSPpVxp-_wFTo_YGvQzaYBpaY9JQo2yc-Z_CvwXm6Rqt-s94wLBzk7dpCJLKUEiQ7-eAzvmkHIBW1Sf2E2XC6pk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645228702</pqid></control><display><type>article</type><title>Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shinde, Arvind M ; Zhai, Jing ; Yu, Kim Wai ; Frankel, Paul ; Yim, John H ; Luu, Thehang ; Kruper, Laura ; Vito, Courtney ; Shaw, Sally ; Vora, Nayana L ; Kirschenbaum, Michele ; Somlo, George</creator><creatorcontrib>Shinde, Arvind M ; Zhai, Jing ; Yu, Kim Wai ; Frankel, Paul ; Yim, John H ; Luu, Thehang ; Kruper, Laura ; Vito, Courtney ; Shaw, Sally ; Vora, Nayana L ; Kirschenbaum, Michele ; Somlo, George</creatorcontrib><description>Abstract Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.</description><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2014.10.008</identifier><identifier>PMID: 25467313</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Aged ; Anthracyclines - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Carboplatin ; Carboplatin - administration & dosage ; Chemotherapy, Adjuvant ; Female ; Hematology, Oncology and Palliative Medicine ; Human epidermal growth factor receptor 2 (HER2) ; Humans ; Inflammatory breast cancer ; Locally advanced breast cancer (LABC) ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Paclitaxel - administration & dosage ; Pathologic complete response (pCR) ; Receptor, ErbB-2 ; Receptors, Estrogen ; Receptors, Progesterone ; Retrospective Studies ; Trastuzumab ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - pathology ; Triple-negative breast cancer (TNBC)</subject><ispartof>Breast (Edinburgh), 2015-02, Vol.24 (1), p.18-23</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-513094e6d816a01f08bfd3ac39bc31024d1c3376a64ab184630d0bf4c04d65243</citedby><cites>FETCH-LOGICAL-c518t-513094e6d816a01f08bfd3ac39bc31024d1c3376a64ab184630d0bf4c04d65243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S096097761400188X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25467313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shinde, Arvind M</creatorcontrib><creatorcontrib>Zhai, Jing</creatorcontrib><creatorcontrib>Yu, Kim Wai</creatorcontrib><creatorcontrib>Frankel, Paul</creatorcontrib><creatorcontrib>Yim, John H</creatorcontrib><creatorcontrib>Luu, Thehang</creatorcontrib><creatorcontrib>Kruper, Laura</creatorcontrib><creatorcontrib>Vito, Courtney</creatorcontrib><creatorcontrib>Shaw, Sally</creatorcontrib><creatorcontrib>Vora, Nayana L</creatorcontrib><creatorcontrib>Kirschenbaum, Michele</creatorcontrib><creatorcontrib>Somlo, George</creatorcontrib><title>Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>Abstract Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.</description><subject>Adult</subject><subject>Aged</subject><subject>Anthracyclines - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Carboplatin</subject><subject>Carboplatin - administration & dosage</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Human epidermal growth factor receptor 2 (HER2)</subject><subject>Humans</subject><subject>Inflammatory breast cancer</subject><subject>Locally advanced breast cancer (LABC)</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pathologic complete response (pCR)</subject><subject>Receptor, ErbB-2</subject><subject>Receptors, Estrogen</subject><subject>Receptors, Progesterone</subject><subject>Retrospective Studies</subject><subject>Trastuzumab</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Triple-negative breast cancer (TNBC)</subject><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQjBCIXRb-ACEfOWyGdux4MhcktFpYpJVAPCRuluN0Jh4SO9jOwPC1fArOZhkeF05-lKur3F1Z9pjCigIVz3ar2qMKcVUA5elqBVDdyU5pyYqcQQV3s1PYCMg367U4yR6EsAOADRPV_eykKLlYM8pOsx9vVexc77ZGE-2GsceIxGMYnQ1poyIGYiyJ3iQot7hV0ezxnFxdvivy0QWzHJVtSOf84OzM1jhG548wWYwSraxGH4hqI_pEiZ1X-qB7YzFvPSKx6FSzm_YJIrrDwcUOvRoP5KuJXaL72o19MmBv9EaVqFF9w37Bnb9Z3RST3aQ3fZ8GVT_M7rWqD_jodj3LPr68_HBxlV-_efX64sV1rktaxbykDDYcRVNRoYC2UNVtw5Rmm1ozCgVvqGZsLZTgqqYVFwwaqFuugTeiLDg7y54vdcepHrDRaJOJXo7eDMofpFNG_o1Y08mt20tebkQSTQWe3hbw7suEIcrBBI19r1JbpiCp4GVRVGso0lO-PNXeheCxPcpQkHM45E4uPZdzOObbFI5Ee_KnxSPpVxp-_wFTo_YGvQzaYBpaY9JQo2yc-Z_CvwXm6Rqt-s94wLBzk7dpCJLKUEiQ7-eAzvmkHIBW1Sf2E2XC6pk</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Shinde, Arvind M</creator><creator>Zhai, Jing</creator><creator>Yu, Kim Wai</creator><creator>Frankel, Paul</creator><creator>Yim, John H</creator><creator>Luu, Thehang</creator><creator>Kruper, Laura</creator><creator>Vito, Courtney</creator><creator>Shaw, Sally</creator><creator>Vora, Nayana L</creator><creator>Kirschenbaum, Michele</creator><creator>Somlo, George</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150201</creationdate><title>Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab</title><author>Shinde, Arvind M ; Zhai, Jing ; Yu, Kim Wai ; Frankel, Paul ; Yim, John H ; Luu, Thehang ; Kruper, Laura ; Vito, Courtney ; Shaw, Sally ; Vora, Nayana L ; Kirschenbaum, Michele ; Somlo, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-513094e6d816a01f08bfd3ac39bc31024d1c3376a64ab184630d0bf4c04d65243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anthracyclines - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Carboplatin</topic><topic>Carboplatin - administration & dosage</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Human epidermal growth factor receptor 2 (HER2)</topic><topic>Humans</topic><topic>Inflammatory breast cancer</topic><topic>Locally advanced breast cancer (LABC)</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pathologic complete response (pCR)</topic><topic>Receptor, ErbB-2</topic><topic>Receptors, Estrogen</topic><topic>Receptors, Progesterone</topic><topic>Retrospective Studies</topic><topic>Trastuzumab</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Triple-negative breast cancer (TNBC)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shinde, Arvind M</creatorcontrib><creatorcontrib>Zhai, Jing</creatorcontrib><creatorcontrib>Yu, Kim Wai</creatorcontrib><creatorcontrib>Frankel, Paul</creatorcontrib><creatorcontrib>Yim, John H</creatorcontrib><creatorcontrib>Luu, Thehang</creatorcontrib><creatorcontrib>Kruper, Laura</creatorcontrib><creatorcontrib>Vito, Courtney</creatorcontrib><creatorcontrib>Shaw, Sally</creatorcontrib><creatorcontrib>Vora, Nayana L</creatorcontrib><creatorcontrib>Kirschenbaum, Michele</creatorcontrib><creatorcontrib>Somlo, George</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shinde, Arvind M</au><au>Zhai, Jing</au><au>Yu, Kim Wai</au><au>Frankel, Paul</au><au>Yim, John H</au><au>Luu, Thehang</au><au>Kruper, Laura</au><au>Vito, Courtney</au><au>Shaw, Sally</au><au>Vora, Nayana L</au><au>Kirschenbaum, Michele</au><au>Somlo, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>24</volume><issue>1</issue><spage>18</spage><epage>23</epage><pages>18-23</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><abstract>Abstract Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Methods Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed. Results Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR. Conclusions Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25467313</pmid><doi>10.1016/j.breast.2014.10.008</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-9776 |
| ispartof | Breast (Edinburgh), 2015-02, Vol.24 (1), p.18-23 |
| issn | 0960-9776 1532-3080 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4596816 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anthracyclines - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Carboplatin Carboplatin - administration & dosage Chemotherapy, Adjuvant Female Hematology, Oncology and Palliative Medicine Human epidermal growth factor receptor 2 (HER2) Humans Inflammatory breast cancer Locally advanced breast cancer (LABC) Middle Aged Neoadjuvant Therapy Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Paclitaxel - administration & dosage Pathologic complete response (pCR) Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Retrospective Studies Trastuzumab Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology Triple-negative breast cancer (TNBC) |
| title | Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T04%3A35%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathologic%20complete%20response%20rates%20in%20triple-negative,%20HER2-positive,%20and%20hormone%20receptor-positive%20breast%20cancers%20after%20anthracycline-free%20neoadjuvant%20chemotherapy%20with%20carboplatin%20and%20paclitaxel%20with%20or%20without%20trastuzumab&rft.jtitle=Breast%20(Edinburgh)&rft.au=Shinde,%20Arvind%20M&rft.date=2015-02-01&rft.volume=24&rft.issue=1&rft.spage=18&rft.epage=23&rft.pages=18-23&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2014.10.008&rft_dat=%3Cproquest_pubme%3E1645228702%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645228702&rft_id=info:pmid/25467313&rft_els_id=1_s2_0_S096097761400188X&rfr_iscdi=true |